Jorge Franco

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

Jorge Franco, Agnieszka K. Witkiewicz, Erik S. Knudsen · Oncotarget · 2014 · 212 citations · Full text

Medicine, Oncology, Pharmacology +17

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

Jorge Franco, Uthra Balaji, Elizaveta Freinkman et al. · Cell Reports · 2016 · 199 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

Agnieszka K. Witkiewicz, Sejin Chung, Rachel Brough et al. · Cell Reports · 2018 · 105 citations · Full text

Medicine, Cancer Biology, Oncology +14

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer

Agnieszka K. Witkiewicz, Nicholas A. Borja, Jorge Franco et al. · Oncotarget · 2015 · 59 citations · Full text

Medicine, Oncology, Pathology +15

Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells

Khrishen Cunnusamy, Ethan Baughman, Jorge Franco et al. · Clinical Immunology · 2014 · 50 citations · Full text

Life Sciences, Immunology, Neurology +16